Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0.1% tacrolimus eye drops for moderate to severe dry eye
ChiCTR1800017513Phase 3Not yet recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Nov 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tacrolimus in dry eye syndrome (DED) (2 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoints: Ocular Surface Disease Index, Tear film breakup time and 2 more. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR1800017513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017513.